{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:28:11Z","timestamp":1782394091415,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jid.2023.10.005","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T08:04:27Z","timestamp":1698134667000},"page":"786-793.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Alterations to the Hidradenitis Suppurativa Serum Proteome with Spleen Tyrosine Kinase Antagonism: Proteomic Results from a Phase 2 Clinical Trial"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7031-2710","authenticated-orcid":false,"given":"Akshay","family":"Flora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-8748","authenticated-orcid":false,"given":"Rebecca","family":"Jepsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9263-3889","authenticated-orcid":false,"given":"James","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5042-3632","authenticated-orcid":false,"given":"John W.","family":"Frew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2023.10.005_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2023.10.005_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5908","article-title":"Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa","volume":"11","author":"Byrd","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2023.10.005_bib3","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jid.2021.07.187","article-title":"Autoantibodies present in hidradenitis suppurativa correlate with disease severity and promote the release of proinflammatory cytokines in macrophages","volume":"142","author":"Carmona-Rivera","year":"2022","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.10.005_bib4","doi-asserted-by":"crossref","first-page":"D472","DOI":"10.1093\/nar\/gkt1102","article-title":"The Reactome pathway KnowledgeBase","volume":"42","author":"Croft","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2023.10.005_bib5","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamadermatol.2021.4926","article-title":"Identification of biomarkers and critical evaluation of biomarker validation in hidradenitis suppurativa: a systematic review","volume":"158","author":"Der Sarkissian","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2023.10.005_bib6","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/exd.14789","article-title":"Baseline clinical, hormonal and molecular markers associated with clinical response to IL-23 antagonism in hidradenitis suppurativa: a prospective cohort study","volume":"32","author":"Flora","year":"2023","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2023.10.005_bib7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/exd.14092","article-title":"Beyond antibodies: B cells in Hidradenitis suppurativa: bystanders, contributors or therapeutic targets?","volume":"29","author":"Frew","year":"2020","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2023.10.005_bib8","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaad.2019.12.044","article-title":"Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: a post hoc analysis of PIONEER 1 and 2 individual patient data","volume":"82","author":"Frew","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2023.10.005_bib9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jid.2020.06.019","article-title":"A\u00a0systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance","volume":"141","author":"Frew","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.10.005_bib10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2023.10.005_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139930","article-title":"Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis","volume":"5","author":"Gudjonsson","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2023.10.005_bib12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/bjd\/ljac007","article-title":"B-cell and complement signature in severe hidradenitis suppurativa that does not respond to adalimumab","volume":"188","author":"Hambly","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2023.10.005_bib13","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jaad.2023.05.076","article-title":"A\u00a0proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa","volume":"89","author":"Jepsen","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2023.10.005_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130522","article-title":"Compartmentalized cytokine responses in hidradenitis suppurativa","volume":"10","author":"Kanni","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2023.10.005_bib15","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jaci.2023.05.012","article-title":"Single-cell transcriptomics suggest distinct upstream drivers of IL-17A\/F in hidradenitis versus psoriasis","volume":"152","author":"Kim","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2023.10.005_bib16","doi-asserted-by":"crossref","first-page":"179.e1","DOI":"10.1016\/j.jtct.2022.12.015","article-title":"A\u00a0phase I trial of SYK inhibition with fostamatinib in the prevention and treatment of chronic graft-versus-host disease","volume":"29","author":"Lin","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jid.2023.10.005_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2015.07.023","article-title":"Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis","volume":"242","author":"Lind","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jid.2023.10.005_bib18","article-title":"Immunopathogenesis of hidradenitis suppurativa and response to Anti-TNF-\u03b1 therapy [published correction appears in JCI Insight 2022;7:e165502]","volume":"5","author":"Lowe","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2023.10.005_bib19","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jid.2019.08.453","article-title":"Enrichment of plasma cells in the peripheral blood and skin of patients with hidradenitis suppurativa","volume":"140","author":"Musilova","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.10.005_bib20","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","article-title":"Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa","volume":"147","author":"Navrazhina","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2023.10.005_bib21","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jaad.2021.07.035","article-title":"The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris","volume":"86","author":"Navrazhina","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2023.10.005_bib22","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jid.2021.02.742","article-title":"In-depth analysis of the hidradenitis suppurativa serum proteome identifies distinct inflammatory subtypes","volume":"141","author":"Navrazhina","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.10.005_bib23","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaci.2022.02.003","article-title":"Insights into hidradenitis suppurativa","volume":"149","author":"van Straalen","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2023.10.005_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade8272","article-title":"Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19","volume":"9","author":"Wigerblad","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.jid.2023.10.005_bib25","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/jdv.16147","article-title":"Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa","volume":"34","author":"Zouboulis","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23029718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23029718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T02:19:41Z","timestamp":1743905981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X23029718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0022202X23029718"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2023.10.005","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alterations to the Hidradenitis Suppurativa Serum Proteome with Spleen Tyrosine Kinase Antagonism: Proteomic Results from a Phase 2 Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2023.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}